Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
Ever since 6-year-old Emily Whitehead became the first pediatric patient to receive CAR-T cell therapy in 2012, when T cells were removed from her body and reprogrammed to attack her leukemia before ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this interview Shahzad Raza, MD, highlights data on ...
ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and ...
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work. What major challenge of traditional CAR-T does the in vivo alleviate/address? In ...
Chimeric antigen receptor (CAR) T-cell therapy has cleared another hurdle on the path to potentially becoming a viable treatment option for people with severe autoimmune diseases, following the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results